AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Dec 7, 2023
32254_dirs_2023-12-07_ca8f11b7-6819-41b0-9e57-1ced04b4ac16.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYEP)
CIK: 0001314102
Period of Report: 2023-12-05
Reporting Person: Ocumension Therapeutics (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-05 | common stock | S | 733758 | $19.91 | Disposed | 2276963 | Direct |
| 2023-12-06 | common stock | S | 266242 | $18.41 | Disposed | 2010721 | Direct |
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7